Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login